Predictive Oncology Inc. Faces Nasdaq Delisting Risk Due to Sub-$1 Stock Price

Reuters

07-12

<a href="https://laohu8.com/S/POAI">Predictive Oncology</a> Inc. Faces Nasdaq Delisting Risk Due to Sub-$1 Stock Price

Predictive Oncology Inc. has announced that it received a letter from the Nasdaq Stock Market LLC, indicating that its common stock has closed below the $1.00 per share minimum bid price requirement for 30 consecutive business days. This places the company out of compliance with Nasdaq's listing standards. The notification, dated July 8, 2025, does not immediately affect the listing of the company's stock. Predictive Oncology has until January 5, 2026, to regain compliance by achieving a bid price of at least $1.00 per share for 10 consecutive business days. If the company fails to meet this requirement, it may be eligible for additional time, provided it meets other listing standards and indicates its intention to resolve the deficiency, possibly through a reverse stock split. The company is actively monitoring the situation and exploring options to address the issue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Predictive Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-004434), on July 11, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550969036"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550969036\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2550969036?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-12 04:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550969036","market":"fut","top_or_hot":-1,"title":"Predictive Oncology Inc. Faces Nasdaq Delisting Risk Due to Sub-$1 Stock Price","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/POAI\">Predictive Oncology</a> Inc. Faces Nasdaq Delisting Risk Due to Sub-$1 Stock Price\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Predictive Oncology Inc. has announced that it received a letter from the Nasdaq Stock Market LLC, indicating that its common stock has closed below the $1.00 per share minimum bid price requirement for 30 consecutive business days. This places the company out of compliance with Nasdaq's listing standards. The notification, dated July 8, 2025, does not immediately affect the listing of the company's stock. Predictive Oncology has until January 5, 2026, to regain compliance by achieving a bid price of at least $1.00 per share for 10 consecutive business days. If the company fails to meet this requirement, it may be eligible for additional time, provided it meets other listing standards and indicates its intention to resolve the deficiency, possibly through a reverse stock split. The company is actively monitoring the situation and exploring options to address the issue.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Predictive Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-004434), on July 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Predictive Oncology Inc. Faces Nasdaq Delisting Risk Due to Sub-$1 Stock Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPredictive Oncology Inc. Faces Nasdaq Delisting Risk Due to Sub-$1 Stock Price\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-12 04:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/POAI\">Predictive Oncology</a> Inc. Faces Nasdaq Delisting Risk Due to Sub-$1 Stock Price\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Predictive Oncology Inc. has announced that it received a letter from the Nasdaq Stock Market LLC, indicating that its common stock has closed below the $1.00 per share minimum bid price requirement for 30 consecutive business days. This places the company out of compliance with Nasdaq's listing standards. The notification, dated July 8, 2025, does not immediately affect the listing of the company's stock. Predictive Oncology has until January 5, 2026, to regain compliance by achieving a bid price of at least $1.00 per share for 10 consecutive business days. If the company fails to meet this requirement, it may be eligible for additional time, provided it meets other listing standards and indicates its intention to resolve the deficiency, possibly through a reverse stock split. The company is actively monitoring the situation and exploring options to address the issue.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Predictive Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-004434), on July 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"醫療保健用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nNDLbjxl5K:1","article_id":"2550969036","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550969036","pubTimestamp":1752265916,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Predictive Oncology Inc. has announced that it received a letter from the Nasdaq Stock Market LLC, indicating that its common stock has closed below the $1.00 per share minimum bid price requirement for 30 consecutive business days. This places the company out of compliance with Nasdaq's listing standards. The notification, dated July 8, 2025, does not immediately affect the listing of the company's stock. Predictive Oncology has until January 5, 2026, to regain compliance by achieving a bid price of at least $1.00 per share for 10 consecutive business days. If the company fails to meet this requirement, it may be eligible for additional time, provided it meets other listing standards and indicates its intention to resolve the deficiency, possibly through a reverse stock split. The company is actively monitoring the situation and exploring options to address the issue.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","POAI":"Predictive Oncology","BK4082":"医疗保健设备"},"translate_title":"Predictive Oncology Inc.因股价低于1美元面临纳斯达克退市风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"POAI":0.9},"content_text":"Predictive Oncology Inc. Faces Nasdaq Delisting Risk Due to Sub-$1 Stock Price\n    \n\n        Predictive Oncology Inc. has announced that it received a letter from the Nasdaq Stock Market LLC, indicating that its common stock has closed below the $1.00 per share minimum bid price requirement for 30 consecutive business days. This places the company out of compliance with Nasdaq's listing standards. The notification, dated July 8, 2025, does not immediately affect the listing of the company's stock. Predictive Oncology has until January 5, 2026, to regain compliance by achieving a bid price of at least $1.00 per share for 10 consecutive business days. If the company fails to meet this requirement, it may be eligible for additional time, provided it meets other listing standards and indicates its intention to resolve the deficiency, possibly through a reverse stock split. The company is actively monitoring the situation and exploring options to address the issue.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Predictive Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-004434), on July 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}